Your browser doesn't support javascript.
loading
Duration of botulinum toxin efficacy in cervical dystonia clinical trials: A scoping review.
Castagna, Anna; Jinnah, Hyder A; Albanese, Alberto.
Affiliation
  • Castagna A; IRCCS Fondazione Don Carlo Gnocchi Onlus, Milan, Italy. Electronic address: acastagna@dongnocchi.it.
  • Jinnah HA; Department of Neurology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
  • Albanese A; Department of Neurology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Parkinsonism Relat Disord ; 125: 107011, 2024 Aug.
Article in En | MEDLINE | ID: mdl-38909588
ABSTRACT

INTRODUCTION:

Botulinum toxin (BoNT) is first-line treatment for cervical dystonia (CD). Treatment of CD with BoNT usually requires injections every 3-4 months for as long as symptoms persist, which can be for the lifetime of the individual. Duration of BoNT effect can impact quality of life since it is important that efficacy is maintained throughout an injection cycle to avoid fluctuations of effect after each injection. There is currently no consensus on how to assess duration of BoNT effect in patients with CD.

METHODS:

A scoping review was conducted to summarize the available evidence from phase 3 clinical trials of BoNT in CD and on the interpretation of the reported duration of effect. The available evidence was analyzed in the context of clinical experience and real-world treatment practices of CD.

RESULTS:

Methods for estimating duration of effect varied across publications; most were based on artificial constructs developed for clinical trials (time until a pre-specified efficacy endpoint was reached) and are not appropriate to apply in clinical practice. Clinical trial outcomes in CD were not objectively evaluated, and did not prioritize patients' needs or focus on factors that impact patients' daily living activities and quality of life.

CONCLUSION:

Better evidence and consistency of reporting for duration of effect for BoNT in CD is needed to help guide clinicians on when reinjection is likely to be required. The goal should be to keep patients as symptom-free as possible with flexible reinjection intervals tailored to individual needs.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Torticollis / Botulinum Toxins Limits: Humans Language: En Journal: Parkinsonism Relat Disord Journal subject: NEUROLOGIA Year: 2024 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Torticollis / Botulinum Toxins Limits: Humans Language: En Journal: Parkinsonism Relat Disord Journal subject: NEUROLOGIA Year: 2024 Type: Article